Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial.

Subjects diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) at biopsy are at increased risk for developing prostate cancer (CaP). A prospective clinical trial was done to determine the safety and tolerability of a novel herbal amalgam, Zyflamend (New Chapter, Inc., Brattleboro, VT), with various dietary supplements in subjects with HGPIN. Men ages 40 to 75 years with HGPIN were eligible. Subjects were evaluated for 18 months. Every 3 months, standard blood chemistries and prostate-specific antigen (PSA) were monitored. Rebiopsy was done every 6 months. Tissue was evaluated for HGPIN or CaP and stained for cyclooxygenase-2, nuclear factor kappaB (NF-kappaB), interleukin-6, and thromboxane. Twenty-three subjects were evaluable. The median age was 64.1 years (range 46-75 years), and the mean (+/- SD) PSA level was 6.13 +/- 3.56 ng/mL. Side effects, when present, were mild and gastrointestinal in nature. There were no reported serious adverse events or toxicities. No significant changes in blood chemistries, testosterone, or cardiac function were noted. Forty-eight percent of subjects demonstrated a 25 to 50% decrease in PSA after 18 months. Of subjects who had the 18-month biopsy, 60% (9 of 15) had benign tissue, 26.7% (4 of 15) had HGPIN in one core, and 13.3% (2 of 15) had CaP at 18 months. A reduction in serum C-reactive protein was observed (95% confidence interval [CI] 0.7-1.7, p = .045). Immunoreactive staining demonstrated a reduction in NF-kappaB in the 18-month samples (95% CI 0.8-3.0, p = .017). Zyflamend alone and in combination with various dietary supplements is associated with minimal toxicity and no serious adverse events when administered orally for 18 months. Further studies are warranted to evaluate these agents in patients who are at risk for CaP.

[1]  K. Iczkowski.  Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. , 2009, Archives of pathology & laboratory medicine.

[2]  F. Montorsi,et al.  Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. , 2009, European urology.

[3]  B. Tomlinson,et al.  In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? , 2008, Molecular nutrition & food research.

[4]  M. Mori,et al.  C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer , 2008, Cancer.

[5]  K. Tateda,et al.  Oral administration of Bifidobacterium longum prevents gut‐derived Pseudomonas aeruginosa sepsis in mice , 2008, Journal of applied microbiology.

[6]  T. Szekeres,et al.  Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. , 2007, Anticancer research.

[7]  J. Mol,et al.  Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. , 2007, Journal of veterinary internal medicine.

[8]  I. Thompson,et al.  Finasteride decreases the risk of prostatic intraepithelial neoplasia. , 2007, The Journal of urology.

[9]  Karla A. Lawson,et al.  Supplemental and Dietary Vitamin E Intakes and Risk of Prostate Cancer in a Large Prospective Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[10]  Amy Subar,et al.  Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. , 2007, Journal of the National Cancer Institute.

[11]  B. Aggarwal,et al.  Zyflamend, a Polyherbal Preparation, Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis Through Down-Regulation of NF-κ B Activation and NF-κ B–Regulated Gene Products , 2007 .

[12]  C. Franceschi,et al.  Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies , 2007, Evidence-based complementary and alternative medicine : eCAM.

[13]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[14]  A. Katz,et al.  The Role of Zyflamend, an Herbal Anti-inflammatory, as a Potential Chemopreventive Agent Against Prostate Cancer: A Case Report , 2007, Integrative cancer therapies.

[15]  R. Newman,et al.  Zyflamend®-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation , 2006, Cancer biology & therapy.

[16]  I. Thompson,et al.  Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification. , 2006, The Journal of urology.

[17]  D. Bostwick,et al.  Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.

[18]  J. Epstein,et al.  Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma , 2006, The American journal of surgical pathology.

[19]  E. Campo,et al.  Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse , 2005, British Journal of Cancer.

[20]  M. Mori,et al.  Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies , 2005, Cancer.

[21]  A. M. Snelling,et al.  Effects of probiotics on the gastrointestinal tract , 2005, Current opinion in infectious diseases.

[22]  M. Remzi,et al.  The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. , 2005, The Journal of urology.

[23]  S. Shany,et al.  The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. , 2005, Anticancer research.

[24]  Liang Cheng,et al.  Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens , 2005, Modern Pathology.

[25]  R. Buttyan,et al.  Zyflamend®, a Unique Herbal Preparation With Nonselective OX Inhibitory Activity, Induces Apoptosis of Prostate Cancer Cells That Lack COX-2 Expression , 2005, Nutrition and cancer.

[26]  P. Humphrey,et al.  High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. , 2005, Urology.

[27]  C. Cordon-Cardo,et al.  Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism , 2005, Clinical Cancer Research.

[28]  W. Isaacs,et al.  The role of inflammation in the pathogenesis of prostate cancer. , 2004, The Journal of urology.

[29]  Liang Cheng,et al.  Nuclear Factor-κB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate , 2004, Clinical Cancer Research.

[30]  R. Paterson,et al.  Prostatic intraepithelial neoplasia: an update. , 2004, Clinical prostate cancer.

[31]  H. Mukhtar,et al.  Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells , 2003, Oncogene.

[32]  M. Steiner,et al.  Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. , 2003, Clinical prostate cancer.

[33]  Yiwei Li,et al.  Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  H. Mukhtar,et al.  Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells , 2002, Oncogene.

[35]  J. Epstein,et al.  Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? , 2001, The Journal of urology.

[36]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[37]  K. Pienta,et al.  Tumor Necrosis Factor-α-induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor-κB by an IκBα “Super-Repressor” , 2000 .

[38]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Wilt,et al.  Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia , 2000, Scandinavian journal of urology and nephrology. Supplementum.

[40]  C. N. Coleman,et al.  Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.

[41]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.

[42]  D. Bostwick,et al.  The pathology of early prostate cancer , 1989, CA: a cancer journal for clinicians.

[43]  J. Epstein,et al.  Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. , 2006, The Journal of urology.